Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
Drugs by status
Phase 2 trials (28)
- methylprednisolone
- afatinib
- plerixafor
- anti cd45 monoclonal antibody
- bpx-501
- busulfan
- danazol
- eltrombopag
- tacrolimus
- genetically engineered hematopoietic stem cells
- hemopoietic stem cell
- Filgrastim
- allogeneic hematopoietic stem cells
- cyclosporine
- stem cells
- allogeneic lymphocytes
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- autologous umbilical cord blood
- rituximab
- sargramostim
- melphalan
- quercetin
- Mozafancogene autotemcel
- autologous hematopoietic stem cells
- fp-045
- tcrαβ+/cd19+ depleted allogeneic hematopoietic stem cell
- jsp191
Phase 1 trials (11)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (32)
- Novartis
- Bellicum Pharmaceuticals
- Sponsor GmbH
- Foresee Pharmaceuticals Co., Ltd.
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- National Heart, Lung, and Blood Institute (NHLBI)
- Academic and Community Cancer Research United
- Rockefeller University
- Baylor University
- Cornell University
- Harvard University
- University of Washington
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
- Indiana University
- Pediatric Brain Tumor Consortium
- Stanford University
- Universidad Autonoma de Madrid
- University of California, San Francisco
- University of Cincinnati
- Good Samaritan Hospital, Cincinnati
- Pennsylvania State University
- Universidad Autonoma de Barcelona
- Methodist Cancer Center, Houston, Texas
- State University of New York, Buffalo
- University of Wisconsin
- University of Paris
- CIEMAT
- CIBERER
- EuroFancolen
- +2 more
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (6)